Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars are gradually making inroads in the outpatient drug ...

As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...

While FDA’s draft guidance may alleviate some of the pressures when biosimilar developers, there are still other significant ...

Biosimilar adoption and market dynamics are reshaping managed care, with the Inflation Reduction Act impacting innovation and market incentives. Specialty pharmaceuticals, particularly GLP-1 drugs, ...

Follow-on biologic makers in China have been working to capitalize on looming patent cliffs of blockbuster biologics. Advancing biosimilars of denosumab (Prolia/Xgeva; Amgen Inc.) and semaglutide are ...

Among other things, the new guidance, which replaces a draft from 2020, provides specific examples of acceptable and unacceptable language when making comparisons of reference prescription products, ...

Fewer biosimilars have been marketed in the United States, compared with Germany and Switzerland, and prices are significantly higher in the US. However, biosimilars that have been introduced in the ...

Serve You Rx, a pharmacy benefit manager, has added two recently approved biosimilars to Stelara to its formulary, the company announced Thursday. Milwaukee, Wisconsin-based Serve You Rx is an ...